4 completed, 1 terminated, 1 unknown. 4 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow enibarcimab: new trials by email Literature Review of enibarcimab trials Research Report on enibarcimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial Adrecizumab (HAM 8101), Placebo - COVID-19 | Phase 2 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 16 | 2022-10-06 | 2024-01-03 |
| Adrecizumab Dose Escalation Safety and Tolerability Evaluation (ADESTE) Adrecizumab - Acute Heart Failure | Phase 2 | Unknown | GREAT Network Italy | 30 | 2019-12-15 | 2021-03-09 |
| Adrecizumab in Cardiogenic Shock Adrecizumab, Placebo - Cardiogenic Shock, Endothelial Dysfunction | Phase 2 / Phase 3 | Completed | Dr. med. Mahir Karakas | 150 | 2019-04-04 | 2021-10-08 |
| Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB Adrecizumab, Placebo - Septic Shock | Phase 2 | Completed | Adrenomed AG | 301 | 2017-12-12 | 2024-02-21 |
| Adrecizumab-LPS Study Endotoxin, Placebo, Adrecizumab - Healthy Volunteers | Phase 1 | Completed | Adrenomed AG | 24 | 2017-01-04 | 2021-02-01 |
| Adrecizumab Phase 1 Trial Placebo, Adrecizumab - Healthy Volunteers | Phase 1 | Completed | Radboud University Medical Center | 24 | 2016-05-23 | 2017-03-15 |
Acute Lung Injury (1) · COVID-19 (1) · Shock, Cardiogenic (1) · Shock, Septic (1)
Adrenomed AG (2) · Dr. med. Mahir Karakas (1) · GREAT Network Italy (1) · Radboud University Medical Center (1) · Universitätsklinikum Hamburg-Eppendorf (1)
Germany (3) · Netherlands (3) · Belgium (1) · France (1) · Indonesia (1)
Peter Pickkers, MD, PhD (2) · Jens Zimmermann, Dr. (1) · Mahir Karakas, MD, MBA (1) · Salvatore Di Somma (1) · Stefan Kluge, MD (1)
PMID 30782906, PMID 34605947, PMID 34895483
2015 (1)